J Korean Med Sci.  2014 Sep;29(9):1320-1324. 10.3346/jkms.2014.29.9.1320.

A Case of Mental Retardation with Paraphilia Treated with Depot Leuprorelin

• Park WS
• Kim KM
• Jung YW
• Lim MH

• KMID: 1794614
• DOI: http://doi.org/10.3346/jkms.2014.29.9.1320

Abstract

Paraphilia is a psychiatric disease that has been difficult to cure. However, recently developed therapeutic methods hold promise. The patient was a 20-yr-old male with chief complaints of continuous masturbation, genital exposure, and aggressive behavior that started 2 yr ago. We administered leuprorelin 3.6 mg intramuscular injection per month, a depot gonadotrophin-releasing hormone analogue, to this patient who a severe mentally retardation with paraphilia. The clinical global impression (CGI)-severity, CGI-improvement and aberrant behavior checklist were performed. After one month, we observed significant improvement in symptoms, such as decreases of abnormal sexual behavior and sexual desire. The GnRH analogues are suggested to be used as an alternative or supplementary therapeutic method for sexual offenders after clinical studies.

Keyword

Paraphilias; Mental Retardation; Leuprorelin

MeSH Terms

Humans
Leuprolide/pharmacology/*therapeutic use
Male
Mental Disorders/complications/diagnosis/*drug therapy
Paraphilias/complications/diagnosis/*drug therapy
Sex Offenses/prevention & control
Sexual Behavior/drug effects
Young Adult
Leuprolide

Reference

1. Garcia FD, Thibaut F. Current concepts in the pharmacotherapy of paraphilias. Drugs. 2011; 71:771–790.

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, D.C.: American Psychiatric Association;2000.

3. Home Office. Home Office statistical bulletin: statistics of mentally disordered offenders in England and Wales. London: Home Office;1998-2001.

4. Ward T, Gannon TA, Birgden A. Human rights and the treatment of sex offenders. Sex Abuse. 2007; 19:195–216.

5. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991; 324:93–103.

6. Wheeler MD, Styne DM. Drug treatment in precocious puberty. Drugs. 1991; 41:717–728.

7. Paterson WF, McNeill E, Reid S, Hollman AS, Donaldson MD. Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty. Arch Dis Child. 1998; 79:323–327.

8. Sifton DW. Physicians desk reference. Montvale: Medical Economics Company, Inc.;2001.

9. Isaac H, Patel L, Meyer S, Hall CM, Cusick C, Price DA, Clayton PE. Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res. 2007; 68:157–163.

10. Thibaut F, Cordier B, Kuhn JM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand. 1993; 87:445–450.

11. Thibaut F, Cordier B, Kuhn JM. Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment? Psychoneuroendocrinology. 1996; 21:411–419.

12. Rösler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med. 1998; 338:416–422.

13. Kim HS, Park WS, Lee JW, Lim MH. A case of an adolescent with paraphilia with depot GnRH analogue (Goserelin). Korean J Psychopharmacol. 2011; 22:230–236.

14. Guy W. ECDU asessment manual for psychopharmacology, revised. Bethesda: US Department of Health, Education, and Welfare;1976.

15. Schroeder SR, Rojahn J, Reese RM. Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation. J Autism Dev Disord. 1997; 27:89–102.

16. Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM. WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry. 2010; 11:604–655.

17. Kádár T, Telegdy G, Schally AV. Behavioral effects of centrally administered LH-RH agonist in rats. Physiol Behav. 1992; 51:601–605.

18. Barron JL, Millar RP, Searle D. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1982; 54:1169–1173.

19. Reilly DR, Delva NJ, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Can J Psychiatry. 2000; 45:559–563.

20. Recommendation Rec (2004) 10 of the Committee of Ministers to member states concerning the protection of the human rights and dignity of persons with mental disorder. Council of Europe. 2004.